- Title
- A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis
- Creators
- J. Theodore Phillips - Baylor University Medical CenterGeorge Rice - Department of Clinical Neurological Science, London Health Science Center, London, Ontario, CanadaLawrence Jacobs - Women & Children's Hospital of BuffaloJoel Oger - University of British ColumbiaDouglas Arnold - McGill UniversityT. Jock Murray - Dalhousie UniversityMary Dibiase - Biogen, Inc., Cambridge, Massachusetts, United StatesVijay Jethwa - BiogenSusan Goelz - BiogenElliot Frohman - The University of Texas Southwestern Medical CenterLuc VANDE GAER - Multiple Sclerosis and Rehabilitation Center, Overpelt, BelgiumThomas Scott - Drexel UniversityJudith Haas - Jüdisches Krankenhaus BerlinEric Eggenberger - Michigan State UniversityMark S Freedman - University of OttawaWilliam Stuart - Multiple Sclerosis Center of AtlantaLuis Cunha - University of Coimbra
- Publication Details
- Clinical therapeutics, v 26(4), pp 511-521
- Publisher
- Excerpta Medica
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:000221229100006
- Scopus ID
- 2-s2.0-2342637729
- Other Identifier
- 991019167342304721
Journal article
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis
Clinical therapeutics, v 26(4), pp 511-521
2004
PMID: 15189748
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Metrics
Details
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Pharmacology & Pharmacy